Wexford Capital’s Moderna MRNA Stock Holding History

Wexford Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,394	Closed	-$100K	–	308
2025 Q4	$100K	Buy	+3,394	New	+$92.2K	0.02%	243
2020 Q2	–	Sell	-82,581	Closed	-$2.47M	–	214
2020 Q1	$2.47M	Buy	+82,581	New	+$1.9M	0.91%	38

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wexford Capital's MRNA Position: Q1 2026 in Review

Wexford Capital sold out of Moderna (MRNA) in Q1 2026, closing a stake of 3,394 shares — an estimated $100K sold.

Wexford Capital first reported a position in MRNA in Q1 2020 and held it in 2 quarters. The position peaked at $2.47M in Q1 2020. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Wexford Capital reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
Wexford Capital sold 3,394 Moderna shares in Q1 2026, an estimated $100K.
Wexford Capital first reported a position in Moderna in Q1 2020 and held it in 2 quarters.
Wexford Capital's Moderna position peaked at $2.47M in Q1 2020.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Wexford Capital's 13F filing for Q1 2026, filed 15 May 2026.